Anti-LATS1 Antibody, clone 1D18 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1D18 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects LATS1. It targets an epitope within 22 amino acids from the N-terminal region.

KLH-conjugated linear peptide corresponding to 22 amino acids from the N-terminal region of human Serine/threonine-protein kinase LATS1.

Quality Control Testing

Evaluated by Western Blotting in HepG2 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected LATS1 in HepG2 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected LATS1 in NIH3T3 and HeLa cell lysates.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected LATS1 in Human placenta tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected LATS1 in NIH3T3 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Serine/threonine-protein kinase LATS1 (UniProt: O95835; also known as EC: 2.7.11.1, Large tumor suppressor homolog 1, WARTS protein kinase, h-warts) is encoded by the LATS1 (also known as WARTS) gene (Gene ID: 9113) in human.  Serine/threonine-protein kinase LATS1 serves as a negative regulator of YAP1 in the Hippo signaling pathway, which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. YAP1 phosphorylation by LATS1 inhibits its translocation into the nucleus to regulate cellular genes that are important for cell proliferation, cell death, and cell migration. LATS1 is shown to be expressed in all adult tissues except in lung and kidney.  It acts as a tumor suppressor and plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. It localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis.  LATS1 negatively regulate G2/M transition by down-regulating CDK1 kinase activity.  It is shown to be phosphorylated by STK3/MST2 at Serine 909 and Threonine 1079, which results in its activation. However, phosphorylation at Serine 464 by NUAK1 and NUAK2 LEADS^™ to diminished protein level and it is essential for regulation of cellular senescence and cellular ploidy.  Blocking of LATS1 and 2 is reported to promote the luminal phenotype and increases the number of bipotent and luminal progenitor cells in most human breast cancers. Absence of LATS stabilizes ERα and the Hippo effectors YAP/TAZ, which control breast cell fate via intrinsic and paracrine mechanisms. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, Affinity^™, reproducibility, and stability over conventional monoclonals. (Ref.: Britschgi, A., et al. (2017). Nature. 541(7638); 541-545; Hao, Y., et al. (2008). J. Biol. Chem. 283(9); 5496-5509).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Affinity is a trademark of Mine Safety Appliances Co.

LEADS is a trademark of Compugen

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.